← Back to Clinical Trials
Recruiting NCT07139496

NCT07139496 Combined Injury-site & Lumbosacral Epidural Spinal Cord Stimulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07139496
Status Recruiting
Phase
Sponsor The University of Hong Kong
Condition Spinal Cord Injuries (SCI)
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2025-09-01
Primary Completion 2028-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Spinal Cord Stimulator

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 5 participants in total. It began in 2025-09-01 with a primary completion date of 2028-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Spinal cord stimulation (SCS) has been shown in previous studies to be capable of restoring motor and autonomic function in patients with chronic complete spinal cord injury (SCI). Clinical studies have demonstrated that SCS enables activation of previously paralyzed muscles, leading to functional improvements in patients in the chronic stage of paralysis through the delivery of activity-based interventions. For most previous studies on SCS in SCI, stimulation was invariably applied to lumbrosacral plexus only. In this study, after signing the consent form, the patient will be assigned for standard surgery with additional implant of the spinal cord stimulator. The investigators propose to conduct the SCS with three phases. For the first phase, SCS over lumbrosacral spinal cord will be activated for 3 months with appropriate stimulation of lower limb muscles for walking together with physiotherapy of individual muscle groups for walking. For the second phase, SCS over lumbrosacral spinal cord will be stopped. SCS over the injury site will be activated for 3 months with appropriate stimulation of lower limb muscles. For the third phase, SCS over both lumbrosacral spinal cord and injury site of spinal cord will be activated for another 3 months with appropriate stimulation of lower limb muscles.

Eligibility Criteria

Inclusion Criteria: 1. American Society of Anesthesiologist (ASA) status I-III 2. Age 18-70 years old 3. Patients with SCI more than 2 years 4. Traumatic or atraumatic spinal cord injury 5. American Spinal Injury Association (ASIA) Impairment Scale A and B 6. Have previous MRI to document extent of spinal cord injury before recruitment Exclusion Criteria: 1. Chronic opioid user 2. Presence of chronic pain condition (pain duration over 3 months) 3. Alcohol or substance abuse 4. active and unaddressed psychiatric diseases

Contact & Investigator

Central Contact

Timmy CW Chan, MBBS

✉ timmychancw@gmail.com

📞 (852)22555679

Frequently Asked Questions

Who can join the NCT07139496 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Spinal Cord Injuries (SCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07139496 currently recruiting?

Yes, NCT07139496 is actively recruiting participants. Contact the research team at timmychancw@gmail.com for enrollment information.

Where is the NCT07139496 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT07139496 clinical trial?

NCT07139496 is sponsored by The University of Hong Kong. The trial plans to enroll 5 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology